NICE issues draft guidance on dupilumab for treating severe asthma with type 2 inflammation

In DRAFT guidance, NICE does not recommend dupilumab as add-on maintenance therapy for treating severe asthma with type 2 inflammation inadequately controlled in people aged ≥12, despite maintenance therapy with high-dose inhaled corticosteroids and another maintenance treatment.

Source:

National Institute for Health and Care Excellence